Bristol Myers Squibb Company $BMY Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 7.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,215,423 shares of the biopharmaceutical company’s stock after selling 328,301 shares during the quarter. Russell Investments Group Ltd.’s holdings in Bristol Myers Squibb were worth $244,265,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Bayban purchased a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Trading Up 0.0%

BMY opened at $63.86 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.10. The business’s 50 day moving average is $59.56 and its two-hundred day moving average is $59.00. The firm has a market cap of $130.45 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Analysts Set New Price Targets

Several brokerages have commented on BMY. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, July 30th. Roth Capital began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.